![Western Blot: Spt6 Antibody [NB100-2582] - siRNA knockdown to confirm the specificity of Spt6 antibody (NB100-2582) in C2C12 myoblasts, WB: 1:2000 dilution. 20 ug whole cell lysate. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Spt6-Antibody-Western-Blot-NB100-2582-img0011.jpg "Western Blot: Spt6 Antibody [NB100-2582] - siRNA knockdown to confirm the specificity of Spt6 antibody (NB100-2582) in C2C12 myoblasts, WB: 1:2000 dilution. 20 ug whole cell lysate. WB image submitted by a verified customer review.")
| Reactivity | Hu, Mu, ChSpecies Glossary |
| Applications | WB, IHC, IP, ChIP, KD |
| Clonality | Polyclonal |
| Host | Rabbit |
| Conjugate | Unconjugated |
| Concentration | 0.2 mg/ml |
| Immunogen | The immunogen recognized by this antibody maps to a region between residue 425 and 475 of human Suppressor of Ty 6 Homolog using the numbering given in entry NP_003161.2 (GeneID 6830). |
| Isotype | IgG |
| Clonality | Polyclonal |
| Host | Rabbit |
| Gene | SUPT6H |
| Purity | Immunogen affinity purified |
| Innovator's Reward | Test in a species/application not listed above to receive a full credit towards a future purchase. |
| Dilutions |
|
||
| Application Notes | Chip reactivity reported in scientific literature (PMID:23503590). Epitope retrieval with citrate buffer pH 6.0 is recommended for FFPE tissue sections. Use in WB reported in scientific publication (PMID: 32427586). Spt6 antibody validated for WB from a verified customer review. |
||
| Control |
|
||
| Reviewed Applications |
|
||
| Publications |
|
| Storage | Store at 4C. Do not freeze. |
| Buffer | TBS, 0.1% BSA |
| Preservative | 0.09% Sodium Azide |
| Concentration | 0.2 mg/ml |
| Purity | Immunogen affinity purified |
| Images | Ratings | Applications | Species | Date | Details | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Enlarge |
reviewed by:
Yongkang Yang |
WB | Human | 03/06/2021 |
Summary
|
||||||||
Enlarge |
reviewed by:
Verified Customer |
WB | Mouse | 04/17/2018 |
Summary
|
Secondary Antibodies |
Isotype Controls |
Research Areas for Spt6 Antibody (NB100-2582)Find related products by research area.
|
|
Breast cancer stem cells survive chemotherapy through S100A10-ANXA2-SPT6 interaction that epigenetically promotes OCT4-mediated stemness By Jamshed Arslan, Pharm D, PhDBreast cancer is the most common cancer among women that causes the greatest number of cancer-related deaths worldwide. After radiotherapy or cytotoxic chemotherapy like paclitax... Read full blog post. |
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
5 | |
4 | |
3 | |
2 | |
1 |
| Yongkang Yang 03/06/2021 |
||
| Application: | WB | |
| Species: | Human |
| Verified Customer 04/17/2018 |
||
| Application: | WB | |
| Species: | Mouse |
![Immunohistochemistry-Paraffin: Spt6 Antibody [NB100-2582] - Sections of human breast carcinoma (left) and mouse squamous cell carcinoma (right). Antibody: Affinity purified rabbit anti- SUPT6H used at a dilution of 1:1,000 (0.2 ug/mL). Detection: DAB](http://images.novusbio.com/fullsize/Spt6-Antibody-Immunohistochemistry-Paraffin-NB100-2582-img0010.jpg "Immunohistochemistry-Paraffin: Spt6 Antibody [NB100-2582] - Sections of human breast carcinoma (left) and mouse squamous cell carcinoma (right). Antibody: Affinity purified rabbit anti- SUPT6H used at a dilution of 1:1,000 (0.2 ug/mL). Detection: DAB")
![Western Blot: Spt6 Antibody [NB100-2582] - Detection of Human Spt6 on HeLa whole cell lysate using NB100-2582. Spt6 was also immunoprecipitated by another rabbit anti-Spt6 antibody.](http://images.novusbio.com/fullsize/Spt6-Antibody-Western-Blot-NB100-2582-img0007.jpg "Western Blot: Spt6 Antibody [NB100-2582] - Detection of Human Spt6 on HeLa whole cell lysate using NB100-2582. Spt6 was also immunoprecipitated by another rabbit anti-Spt6 antibody.")
![Effects on autophagic activity and dendritic length of neurons exposed to supernatant from HIV-1-infected microglia in combination with morphine. (A) Representative images of neurons with the indicated treatments. Sup, supernatant from uninfected [HIV(-)] and HIV-1-infected [HIV(+)] microglia. Cells were immunolabeled with antibodies to the autophagic activity marker p62/SQSTM1 (red) and the neuronal cell-type-specific marker MAP2 (green). DAPI (blue) staining indicates cell nuclei. (B) Quantification of p62/SQSTM1 immunoreactivity from (A). Data are presented as the percentage of control cells which was set at 100; F(5,24) = 5.882, p = 0.0011; ∗p < 0.05 when compared to HIV(+)Sup + morphine treatment. (C) Western blotting analysis of p62/SQSTM1 and LAMP1 expression levels for the indicated treatments. GAPDH was used as a loading control. Blots are representative of three independent experiments. (D) Measurement of dendrite length from (A). F(5,24) = 26.15, p = < 0.0001; Φp < 0.05 when compared to morphine; Ψp < 0.05 when compared to HIV(-)Sup; Ωp < 0.05 when compared to HIV(-)Sup + morphine; #p < 0.05 when compared to HIV(+)Sup; and ∗p < 0.05 when compared to HIV(+)Sup + morphine treatment. Error bars show the SEM for five randomly selected fields totaling at least 100 cells from each group. Image collected and cropped by CiteAb from the following open publication (//journal.frontiersin.org/Article/10.3389/fmicb.2015.00653/abstract), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2582_rabbit-polyclonal-spt6-antibody-2322024819982.jpg "Effects on autophagic activity and dendritic length of neurons exposed to supernatant from HIV-1-infected microglia in combination with morphine. (A) Representative images of neurons with the indicated treatments. Sup, supernatant from uninfected [HIV(-)] and HIV-1-infected [HIV(+)] microglia. Cells were immunolabeled with antibodies to the autophagic activity marker p62/SQSTM1 (red) and the neuronal cell-type-specific marker MAP2 (green). DAPI (blue) staining indicates cell nuclei. (B) Quantification of p62/SQSTM1 immunoreactivity from (A). Data are presented as the percentage of control cells which was set at 100; F(5,24) = 5.882, p = 0.0011; ∗p < 0.05 when compared to HIV(+)Sup + morphine treatment. (C) Western blotting analysis of p62/SQSTM1 and LAMP1 expression levels for the indicated treatments. GAPDH was used as a loading control. Blots are representative of three independent experiments. (D) Measurement of dendrite length from (A). F(5,24) = 26.15, p = < 0.0001; Φp < 0.05 when compared to morphine; Ψp < 0.05 when compared to HIV(-)Sup; Ωp < 0.05 when compared to HIV(-)Sup + morphine; #p < 0.05 when compared to HIV(+)Sup; and ∗p < 0.05 when compared to HIV(+)Sup + morphine treatment. Error bars show the SEM for five randomly selected fields totaling at least 100 cells from each group. Image collected and cropped by CiteAb from the following open publication (//journal.frontiersin.org/Article/10.3389/fmicb.2015.00653/abstract), licensed under a CC-BY license. Not internally tested by Novus Biologicals.")
![Western Blot Brg1 Antibody [Unconjugated]](https://images.novusbio.com/images2/Brg1_AF5738_Western_Blot_5829.jpg)
![Immunocytochemistry Brg1 Antibody [Unconjugated]](https://images.novusbio.com/images2/Brg1_AF5738_Immunocytochemistry_11663.jpg)
![Immunocytochemistry Brg1 Antibody [Unconjugated]](https://images.novusbio.com/images2/Brg1_AF5738_Immunocytochemistry_11664.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).](https://images.novusbio.com/images/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-HRP-Western-Blot-NB7160-img0001.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP] [NB7160] - Western blot showing vemurafenib treatment in BRAFV600E CRC cells inhibits fission mediator DRP1 with no significant effect on fusion proteins (Mfn1 & 2) using MFN-1 antibody (NBP1-51841) and corresponding secondary antibody, goat anti-rabbit IgG-HRP (NB7160). Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/33738242).")
![Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.](https://images.novusbio.com/images/Rabbit--Mouse-IgG-Isotype-Control-Flow-Cytometry-NBP2-24891-img0001.jpg "Flow Cytometry: Rabbit IgG Isotype Control [NBP2-24891] - Intracellular FACS analysis of mouse TLR6 polyclonal antibody (red), rabbit isotype control (green), RAW cells alone (shaded). Two micrograms of antibodies were used. Goat anti-rabbit FITC (Novus, 20302) was used as secondary.")
